As a 2025 Schmidt Science Fellow, Aman plans to advance CAR-cell immunotherapy for cancer and other diseases, making it more effective and safer to improve patient outcomes worldwide.
CAR-engineered immune cells are designed to target and eliminate diseased cells. While CAR T cell therapy has shown success in cancer treatment, the therapy can sometimes encounter resistance and cause severe side effects.
Aman’s research focuses on developing CAR-cell therapies with enhanced efficacy, less resistance and reduced adverse effects. This will broaden the application of CAR-based immunotherapy to various diseases, paving the way for new and improved therapies to benefit a broader range of patients.
Aman will pivot from Biomedical Sciences to Immunology